Biotech · Private company
Pulmotect, Inc.
Track this companyFree. Adds Pulmotect, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- PUL-042Phase 2 · Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- PUL-042 Inhalation SolutionPhase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- PUL-042Phase 1 · Hematologic DiseasesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)PHASE2 · RECRUITING · started Jun 27, 2025ClinicalTrials.gov NCT06665100 · fetched Nov 12, 2026
- A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant RecipientsPHASE1 · WITHDRAWN · started Dec 1, 2024ClinicalTrials.gov NCT03097796 · fetched Nov 12, 2026
- The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 InfectionPHASE2 · COMPLETED · started Jun 16, 2020ClinicalTrials.gov NCT04312997 · fetched Nov 12, 2026
- The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2PHASE2 · COMPLETED · started Jun 9, 2020ClinicalTrials.gov NCT04313023 · fetched Nov 12, 2026